Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor

Abstract

Here, we describe a fatal serious adverse event observed in a patient infused with autologous T-cell receptor (TCR) transduced T cells. This TCR, originally obtained from a melanoma patient, recognizes the well-described HLA-A*0201 restricted 26-35 epitope of MART-1, and was not affinity enhanced. Patient 1 with metastatic melanoma experienced a cerebral hemorrhage, epileptic seizures, and a witnessed cardiac arrest 6 days after cell infusion. Three days later, the patient died from multiple organ failure and irreversible neurologic damage. After T-cell infusion, levels of IL-6, IFN-γ, C-reactive protein (CRP), and procalcitonin increased to extreme levels, indicative of a cytokine release syndrome or T-cell-mediated inflammatory response. Infused T cells could be recovered from blood, broncho-alveolar lavage, ascites, and after autopsy from tumor sites and heart tissue. High levels of NT-proBNP indicate semi-acute heart failure. No cross reactivity of the modified T cells toward a beating cardiomyocyte culture was observed. Together, these observations suggest that high levels of inflammatory cytokines alone or in combination with semi-acute heart failure and epileptic seizure may have contributed substantially to the occurrence of the acute and lethal event. Protocol modifications to limit the risk of T-cell activation-induced toxicity are discussed.

Is autoimmunity the Achilles' heel of cancer immunotherapy?

“…The adoptive transfer of TCR transgenic T cells and CAR T cells can cause severe immunotoxicity owing to cytokine release upon target recognition 95,96 . Cytokine-release syndrome can be effectively managed with cytokine blockade 29 .…”

The Principles of Engineering Immune Cells to Treat Cancer

“…One patient died from cytokine release with a clinical syndrome like that observed with CAR T cells (van den Berg et al, 2015). Whether MART-1 is a valid target for engineered T cells remains an open question.…”

Adoptive CD8+ T cell therapy against cancer:Challenges and opportunities

“…The CD19 CAR-T therapy always induces transient or prolonged lack of B cells, resulting in adaptive immunoglobulin deficiency [83]. Severe toxicity was reported for multiple tissues damage including the skin, eyes, and ears in a late stage clinical trial enrolled 36 patients with metastatic melanoma received MART-1 or gp100-specific TCR-T cells [84,85].…”